ATHA vs. PLX, JATT, CVM, CGTX, ALVR, DTIL, TIL, ATRA, CRIS, and ELUT
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), CEL-SCI (CVM), Cognition Therapeutics (CGTX), AlloVir (ALVR), Precision BioSciences (DTIL), Instil Bio (TIL), Atara Biotherapeutics (ATRA), Curis (CRIS), and Elutia (ELUT). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
Protalix BioTherapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 5.0% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Protalix BioTherapeutics had 10 more articles in the media than Athira Pharma. MarketBeat recorded 12 mentions for Protalix BioTherapeutics and 2 mentions for Athira Pharma. Protalix BioTherapeutics' average media sentiment score of 1.88 beat Athira Pharma's score of 0.22 indicating that Athira Pharma is being referred to more favorably in the news media.
Protalix BioTherapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 754.70%. Athira Pharma has a consensus price target of $19.00, suggesting a potential upside of 755.86%. Given Protalix BioTherapeutics' higher possible upside, analysts clearly believe Athira Pharma is more favorable than Protalix BioTherapeutics.
Protalix BioTherapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500.
Athira Pharma received 12 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 56.67% of users gave Athira Pharma an outperform vote.
Protalix BioTherapeutics has a net margin of 11.48% compared to Protalix BioTherapeutics' net margin of 0.00%. Athira Pharma's return on equity of 19.48% beat Protalix BioTherapeutics' return on equity.
Summary
Protalix BioTherapeutics beats Athira Pharma on 9 of the 15 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
